{"id":"W4416748292","doi":"10.1007/s00415-025-13530-1","title":"Is therapy-free remission a realistic goal with cladribine tablets in multiple sclerosis? New insights into the mechanism of action and clinical implications of immune reconstitution with cladribine tablets in MS therapy","year":2025,"lang":"en","type":"article","venue":"Journal of Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Biogen; Celgene; Deutschen Multiple Sklerose Gesellschaft; Multiple Sclerosis Society; Alexion Pharmaceuticals; Bristol-Myers Squibb; Alzheimer Society; Teva Pharmaceutical Industries; Merck KGaA; Daiichi Sankyo Europe; Sanofi; Argenx; Deutsche Alzheimer Gesellschaft; Universitätsklinikum Essen","keywords":"Cladribine; Multiple sclerosis; Clinical trial; Immune system; Teriflunomide; Mechanism (biology); Disease","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001523937,0.0001856846,0.0007367887,0.0003383028,0.0001659282,0.001220404,0.0003731866,0.0009211677,0.002059979],"category_scores_gemma":[0.002988448,0.0001112503,0.0004809877,0.0002844743,0.0006505855,0.001515909,0.0003352309,0.001529869,0.0003263013],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004861998,"about_ca_system_score_gemma":0.0007992274,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004443191,"about_ca_topic_score_gemma":0.001165996,"domain_scores_codex":[0.9994934,0.000243792,0.00007477582,0.00004154627,0.0001156719,0.00003072108],"domain_scores_gemma":[0.998498,0.001081781,0.0002054858,0.000031953,0.0001367545,0.00004609622],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","study_design_scores_codex":[0.001142985,0.0001189784,0.001022599,0.01512816,0.000285736,0.000745532,0.0004953122,0.0004752157,0.005250978,0.01542543,0.01385439,0.9460546],"study_design_scores_gemma":[0.0005600974,0.002828092,0.01002216,0.02227003,0.0007563287,0.005080379,0.001069201,0.001313359,0.004261165,0.02240203,0.9293387,0.00009847856],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.003649646,0.9867238,0.0005248785,0.006708041,0.0003781611,0.00001389507,0.00003001948,0.000007259152,0.001964328],"genre_scores_gemma":[0.05235769,0.9399217,0.001137557,0.003542589,0.001871698,0.00004677909,0.00004644618,0.000006570223,0.001068953],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.002059979,"threshold_uncertainty_score":0.008059442,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1180017137197141,"score_gpt":0.360912686196836,"score_spread":0.2429109724771218,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}